EcoDrugPlus

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSCMIG00000006245
Gene Symbol: FGFR2
3 Cross references
219 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSCMIG00000008720
Gene Symbol: FGFR3
3 Cross references
197 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSCMIG00000009136
Gene Symbol: FLT3
3 Cross references
134 Possible Orthologues:

Fms Related Tyrosine Kinase 4

Ensembl ID : ENSCMIG00000006584
Gene Symbol: FLT4
3 Cross references
203 Possible Orthologues:

Folate Receptor Alpha-Like

Ensembl ID : ENSCMIG00000006999
Gene Symbol: LOC103171823
3 Cross references
436 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSCMIG00000004781
Gene Symbol: FRK
3 Cross references
217 Possible Orthologues:

Galectin 3

Ensembl ID : ENSCMIG00000000195
Gene Symbol: LGALS3
3 Cross references
232 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-3-Like

Ensembl ID : ENSCMIG00000000996
Gene Symbol: LOC103172449
2 Cross references
125 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha1 Subunit

Ensembl ID : ENSCMIG00000011710
Gene Symbol: GABRA1
3 Cross references
199 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha4 Subunit

Ensembl ID : ENSCMIG00000010750
Gene Symbol: GABRA4
4 Cross references
203 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha6 Subunit

Ensembl ID : ENSCMIG00000011733
Gene Symbol: GABRA6
2 Cross references
266 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Beta2 Subunit

Ensembl ID : ENSCMIG00000007411
Gene Symbol: GABRB2
3 Cross references
291 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).